Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016 | Zendy

Michael A. Pfaller | Zendy; Robert K. Flamm | Zendy; Rodrigo E. Mendes | Zendy; Jennifer M Streit | Zendy; Jennifer I. Smart | Zendy; Kamal Hamed | Zendy; Leonard R Duncan | Zendy; Hélio S. Sader | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016

Author(s) -

Michael A. Pfaller,

Robert K. Flamm,

Rodrigo E. Mendes,

Jennifer M Streit,

Jennifer I. Smart,

Kamal Hamed,

Leonard R Duncan,

Hélio S. Sader

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01566-18

Subject(s) - microbiology and biotechnology , moraxella catarrhalis , cephalosporin , enterococcus faecalis , biology , staphylococcus aureus , pseudomonas aeruginosa , streptococcus pneumoniae , haemophilus influenzae , klebsiella pneumoniae , acinetobacter baumannii , pneumonia , klebsiella pneumonia , antibiotics , medicine , escherichia coli , bacteria , biochemistry , genetics , gene

Ceftobiprole is an advanced cephalosporin with potent activity against Gram-positive and Gram-negative bacteria that has been approved in many European and non-European countries to treat community- and hospital-acquired pneumonia (excluding ventilator-associated pneumonia). This study reports on the activity of ceftobiprole against a large set of clinical isolates obtained from hospitalized patients in the United States in 2016 that caused serious infections, including pneumonia, bacteremia, and skin and skin structure infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research